We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Hematology Analyzer Market to Surpass USD 2 Billion by 2024

By LabMedica International staff writers
Posted on 11 Jul 2017
The global hematology analyzer market is expected to surpass USD 2 billion, driven by the introduction of new and innovative products & methods, with sales of 6-part differential analyzers to register the fastest growth and hospitals to account for the highest share.

These are the latest findings of Persistence Market Research (New York, NY, USA), a third-platform market research firm.

The key players in the global hematology analyzer market are launching innovative products in an attempt to retain and increase their market share. More...
Moreover, advancements in the field of information technology have created a demand for IT-driven medical information networks in the healthcare sector, aiding the effective collection and analysis of hematology test data. These factors are driving the demand for hematology analyzers across the world. Additionally, increasing awareness about chronic diseases and higher demand for hematology analyzers from healthcare settings, led by a rising geriatric population, are expected to further drive the market growth.

Sales of 6-part differential analyzers are expected to register the fastest CAGR of 6.1% through 2024 to reach USD 230 million, due to their widespread adoption globally and a comparatively quicker pace of innovation in this differential segment. However, 5-part differential analyzers are estimated to remain the most sought-after, with sales growing at a CAGR of 5.6% to reach USD 1,386.7 million by 2024-end.

On the basis of modality, standalone hematology analyzers will continue to be the most lucrative in the market and grow at a CAGR of 5.8% through 2024, as they remain the preferred choice among large-scale hospitals in the developed economies. Additionally, sales of point of care hematology analyzers are estimated to reach USD 929.2 million by 2024-end.

Hospitals are expected to account for the largest market share and remain the biggest end-users of hematology analyzers, globally. Sales of hematology analyzers in hospitals are estimated to reach almost USD 600 million in 2017, with diagnostic centers to be the emerging end-users and record a CAGR of 5.7% in sales through 2024.

North America is expected to continue dominating the global hematology analyzer market, with sales in the region surpassing USD 700 million by 2024-end. The 6-part differential segment is expected to record the highest CAGR of 6.3% in the North America hematology analyzer market from USD 72 million in 2016 to USD 117 million by the end of 2024. Asia Pacific will be the world’s fastest growing market for hematology analyzers and record a CAGR of 7.1% through the forecast period.

However, macro-economic and geopolitical uncertainties related to monetary and fiscal policies are impacting the players in the global hematology analyzer market. Moreover, liquidity risk is expected to act as a constraint to the growth of small-scale manufacturers of hematology analyzers. Other factors likely to hamper the market growth are regulatory challenges for obtaining approval of hematology analyzers, and increasing excess and obsolete inventories, such as semi-automatic hematology analyzers, due to the rise in automation.

Related Links:
Persistence Market Research


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.